Compare Las Vegas Sands Corp. (LVS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs 10X Genomics Inc — how do they compare? Las Vegas Sands Corp. trades at $45.45 (market cap $29.44B), while 10X Genomics Inc trades at $57.21 (market cap $7.61B). The key difference: Las Vegas Sands Corp. is far larger — about 3.9× 10X Genomics Inc's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| LVS | TXG | |
|---|---|---|
Market Cap | $29.44B | $7.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $58.57 |
52-Week Low | $44.78 | $11.34 |
Enterprise Value | $41.33B | $7.14B |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.46, down 0.68% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates at $0.59 versus $0.757 expected, but revenue growth remains robust with 2025 revenue at $13.02B. Analyst consensus is strongly bullish with a $60.75 price target and no sell ratings among 49 analysts. Recent news highlights corporate responsibility efforts and operational achievements in Macao.
The outlook is supported by strong fundamentals including a 12.59% net income margin and positive cash flow trends, but risks include high debt levels and competitive pressures. Upside potential exists if earnings rebound in Q3, aligning with analyst optimism, though technical weakness near support at $44 requires monitoring for stability.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
